Esperion, announced that John Harlow will join the company as Chief Commercial Officer, effective November 17, 2025. In his new role, Mr. Harlow will become part of Esperion’s Executive Leadership Team and report directly to Sheldon Koenig, the President and CEO.

Health Technology Insights: CareDx Names Jeffrey Teuteberg as Chief Medical Officer

Sheldon Koenig said, We are excited to have John join Esperion at this critical stage of our growth as we expand adoption of our therapies in the United States and continue building our presence worldwide. John brings extensive experience in developing and scaling commercial organizations and a proven record of driving revenue and leading high-performing teams. His leadership will help ensure that our cardiovascular risk reduction therapies reach patients who need them most.

Health Technology Insights: Wellpoint DC Earns First NCQA Accreditation with Perfect Score

Mr. Harlow is an accomplished executive with more than twenty years of leadership experience at pharmaceutical companies of various sizes across multiple therapeutic areas. He most recently served as Chief Commercial Officer at Melinta Therapeutics, where he established a strong commercial platform that significantly increased revenue and achieved approximately eighty-five percent growth from 2020 to 2024 while managing a team of about eighty professionals across sales, marketing, market access, trade, training, and operations. He previously held the role of Chief Commercial Officer at Baudax Bio and held senior commercial positions at Recro Pharma, Endo Pharmaceuticals, Shionogi USA, Pfizer, Alpharma, and Novartis. Earlier in his career, he was an equity research analyst covering large-cap pharmaceutical companies at Bank of America Merrill Lynch and began his career at Janssen Pharmaceuticals as a sales representative and marketing communications specialist.

Mr. Harlow holds an MBA in Pharmaceutical Management and Marketing from Seton Hall University and a Bachelor of Science in Biology from Lehigh University.

John Harlow said, I am thrilled to join Esperion as the company continues to transform cardiovascular disease prevention for millions of patients. Esperion’s dedication to innovation, its growing international presence, and the proven benefits of NEXLETOL and NEXLIZET present a remarkable opportunity to make a meaningful impact on cardiovascular care. I look forward to working with the team to accelerate growth and expand access to these important therapies.

Health Technology Insights: Bristol Myers Squibb Showcases Sotyktu Data in PsA and Lupus Studies

To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com